Novo Nordisk Pharmatech A/S: Financial statements 2013
CVR: 13246149
Source: annual report 2013, Danish Business Authority
01/01/2013 – 31/12/2013
Novo Nordisk Pharmatech A/S (CVR 13246149) has filed annual accounts for 2013. In 2013, the company reported revenue of DKK 497,979,000 and a net result of DKK 46,703,000. The profit margin was 9.4%. Equity in the 2013 report amounted to DKK 304,474,000. The solvency ratio was 71.2%. The company had 141 employees in the financial year.
- Revenue
- DKK 497,979,000
- Gross Profit
- DKK 170,714,000
- Profit/Loss
- DKK 46,703,000
- Equity
- DKK 304,474,000
- Total Assets
- DKK 427,784,000
- Employees
- 141
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2013
Novo Nordisk Pharmatech A/S has published its annual report for 2012.
About Novo Nordisk Pharmatech A/S
Novo Nordisk Pharmatech A/S is a Danish company of the type Aktieselskab based in Køge, founded in 1989. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named FEF CHEMICALS A/S and FERROSAN FINE CHEMICALS A/S. The management consists of Ulla Grove Krogsgaard Thomsen. The board consists of Mette Sofie Mørck Jarl (chair), Christian Brøgger Stolberg, Jacob Sten Petersen and Joachim Juel Hagemeister. The company is owned by NOVO NORDISK A/S. The company has 489 employees (2026). In 2025, the company reported revenue of DKK 1,041,584,000 and a net result of DKK 113,891,000 compared with DKK 60,619,000 the year before. Equity in the 2025 report amounted to DKK 2,441,318,000.
